CanCuRX

CanCuRX Overview

CanCuRX is a preclinical-stage biopharmaceutical company aiming to improve survival for patients with pancreatic cancer through the development of a novel treatment based on the properties of a mushroom-derived compound that arrests pancreatic cell growth. CanCuRX is working with the Carmel Innovations Fund of the University of Haifa. CanCuRX has patents registered for the mushroom strain, the extract prepared from it, and the treatment process.

Cumulative Funding Raised Over Time ($)

Latest News

Jan 24, 2019 · www.jpost.com

growth-positive

https://www.jpost.com/Jerusalem-Report/Marketplace-Fuad-Fares-Druze-hi-tech-pioneer-578498

The article discusses the success story of Prof. Fuad Fares, a Druze biomedical scholar and entrepreneur from Israel. Prof. Fares founded and directs the Department of Molecular Genetics at Haifas Carmel Medical Center and has achieved significant success in his field. The article highlights the lack of inclusivity in Israels hi-tech start-up industry and praises Prof. Fares as a role model for his community. It mentions that OPKO Health acquired Prolor Biotech, a company founded by Prof. Fares, for $480 million in 2013. The article also touches on Prof. Fares journey to success, his motivation, his research on long-lasting proteins, and his work in finding new tools for cancer treatment. Overall, the article has a growth-positive impact on OPKO Health and highlights the theme of inclusive innovation.

Acquisition

Funding

Team Members

2

Employees: 1-10

Web & Social Links

Locations

Eshkol Tower, University of Haifa, 3498838 Israel

Photos & Videos

1 item(s)

CanCuRX Internal

Recent Updates

No update log entries.

Note: Free-text notes visible in the original Finder "Internal" tab are not present in the imported profile data. Only the update audit log is available.

Admin Info